OOIR: Observatory of International Research

Papers

(The H4-Index of Dermatologic Therapy is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Case report: Pyogenic granuloma—just salt, a simple and pain‐free treatment	67
Switch from ustekinumab to guselkumab in patients with psoriasis in real clinical practice using the “minimal disease activity” parameter	62
Issue Information	60
Exploring and expanding frontiers in dermatology: Indigenous African dermatology	48
Cryptococcal meningitis associated with interleukin‐17 inhibitor use for psoriasis	46
Epidemiology, clinical presentation, and management of pemphigoid nodularis: An update from Iran	43
Fat herniation over striae distansea in focal dermal hypoplasia treated with 2940 nm Er: YAG Laser	41
Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis	39
Macrophage Migration Inhibitory Factor and Gene Polymorphism (rs755622G>C) in Unstable Vitiligo Patients	38
Reply to “A case of symmetrical drug‐related intertriginous and flexural exanthema‐like eruption associated with Pfizer COVID ‐19 vaccination” by Manaa et al.	38
Ultraviolet A Combined with Narrow‐Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow‐Band Ultraviolet B	38
Intrapleural infections in patients with subcutaneous panniculitis‐like T‐cell lymphoma are susceptible to hemophagocytic lymphohistiocytosis	35
The case of granuloma annulare associated with SARS‐CoV ‐2 infection	35
Two birds with one stone: Successful treatment with methotrexate in a patient with generalized eruptive keratoacanthoma of Grzybowski and rheumatoid arthritis	35
The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gain‐of‐function mutation in STAT1 : A case‐report	34
Cutaneous lupus erythematosus variants responsive to J anus kinase inhibition	33
Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series	33
Ulcerative injection site reaction after third COVID ‐19 vaccine dose with mRNA ‐1273	32
Dapsone in hidradenitis suppurativa: A case series of 56 patients	32
Treatments for disease damage in cutaneous lupus erythematosus: A narrative review	32
Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib	31
	31
COVID ‐19 vaccine‐induced urticarial vasculitis	31
Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients	30
Severe hidradenitis suppurativa (acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab	30

Real‐World Guselkumab Response and Drug Survival in Australian Patients With Psoriasis: Results From the Australasian Psoriasis Registry	29
Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis	29
New‐onset systemic lupus erythematosus after ChAdOX1 nCoV‐19 and alopecia areata after BNT162b2 vaccination against SARS‐CoV‐2	28
Tofacitinib in resistant chronic actinic dermatitis: A case series	28
Comparison of Green‐Synthesized Silver Nanoparticle Shampoo Created by Moringa and Bergamot Extraction Versus 2% Ketoconazole Shampoo for Scalp Seborrheic Dermatitis: A Prospective, Randomized, Double	28